US2014179925A1PendingUtilityA1
Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
Est. expirySep 4, 2029(~3.1 yrs left)· nominal 20-yr term from priority
C07D 405/06C07D 401/06C07D 215/14C07D 307/52C07D 213/50C07D 295/192C07D 409/06C07D 333/22
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2 wherein the variables have the meaning disclosed in the specification
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups, or with one or two alkyl groups having 1 to 6 carbons, or one or two carbons of said rings being attached to an oxygen to form keto groups and said 4, 5, 6 or 7 membered ring optionally being condensed with an aromatic or non-aromatic 5 or 6 membered ring that optionally includes 1 or heteroatoms selected from N, O and S;
R 3 is independently selected from H, alkyl of 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons, aryl-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons, or hetero-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or R 3 is CO—R 7 , SO 2 R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, alkyl of 1 to 20 carbons substituted with and NH 2 group or with an NH—COalkyl group where the alkyl group has one to 6 carbons, aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons or heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
the wavy lines represent bonds connected to carbons having R or S configuration;
the dashed lines represent a bond or absence of a bond with the proviso that the ring containing the dashed lines is aromatic;
m, n and q are integers independently selected from 0, 1, 2 or 3 with the proviso that the sum of m, n and q is 2 or 3;
s is zero (0) or when X is N then s is zero (0) or 1;
W, X and Y independently represent a CH, CR 5 , CR 6 or a heteroatom selected independently of N, O and S, and
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, halogen substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, phenyl, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons or a pharmaceutically acceptable salt of said compound with the proviso that Formula 1 does not cover compounds where R 4 is H, R 1 and R 2 jointly with the nitrogen form a pyrrolidino or morpholino ring, the sum of m, n and q is 3, and where none of W, X and Y represent a heteroatom with the further proviso that the formula does not cover the compounds of the formula below
2 . The use of claim 1 , wherein the sum of the integers m, n and q is 3.
3 . The use of claim 2 , wherein one of the W, X and Y groups is N.
4 . The use of claim 3 , wherein R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring.
5 . The use of claim 2 , wherein none of the W, X and Y groups is a heteroatom.
6 . The use of claim 5 wherein R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring.
7 . The use of claim 1 , wherein the sum of the integers m, n and q is 2 and at least one of W, X and Y is a heteroatom.
8 . The use of claim 7 , wherein only one of W, X and Y represents a heteroatom.
9 . The use of claim 7 , wherein two of the W, X and Y groups each represent an independently selected heteroatom.
10 . The use of claim 1 , wherein R 4 is H.
11 . The use of claim 10 , wherein both R 3 groups are H.
12 . The use of claim 10 , wherein one R 3 group is H and the other R 3 group is CO—R 7 or alkyl of 1 to 20 carbons.
13 . The use of claim 10 , wherein R 3 is independently selected from H and alkyl of 1 to 10 carbons.
14 . The use of claim 1 , wherein R 4 is CO—R 8 .
15 . The use of claim 1 , wherein R 1 and R 2 together with the nitrogen form a 4, 5, 6 or 7 membered ring.
16 . The use of claim 15 , wherein R 1 and R 2 together with the nitrogen form a 5 membered ring.
17 . The use of claim 15 , wherein R 1 and R 2 together with the nitrogen form a 6 membered ring.
18 . The use of claim 1 , wherein both R 5 and R 6 are hydrogen.
19 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups or with one or two alkyl groups having 1 to 6 carbons;
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroalkyl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons,
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and
the wavy lines represent bonds of the alpha or beta configuration, or any pharmaceutically acceptable salt of said compound.
20 . The use of claim 19 , wherein R 4 is H.
21 . The use of claim 19 , wherein both R 3 groups are H.
22 . The use of claim 19 , wherein both R 5 and R 6 are hydrogen.
23 . The use of claim 19 , wherein the compound has the formula
or a pharmaceutically acceptable salt of said compound.
24 . The use of claim 23 , wherein R 4 is H.
25 . The use of claim 23 , wherein both R 3 groups are H.
26 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups, or with one or two alkyl groups having 1 to 6 carbons,
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, aryl or heteroaryl, cycloalkyl of 3 to 6 carbons, aryl-alkyl aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroaryl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, thioxy of 1 to 3 carbons and phenyl, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, and the wavy lines represent bonds connected to carbons having R or S of configuration, with the proviso that the claim does not cover compounds where R 4 is H, R 1 and R 2 jointly with the nitrogen form a pyrrolidino or morpholino ring, or any pharmaceutically acceptable salt of said compound.
27 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where X is O or S;
R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 5 or 6 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups or cyano groups with one or two alkyl groups having 1 to 6 carbons,
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroaryl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and
the wavy lines represent bonds connected to carbons having R or S configuration, or any pharmaceutically acceptable salt of said compound
with the further proviso that the claim does not cover the compound shown below
28 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen or cyano groups or with one or two alkyl groups having 1 to 6 carbons, or one or two carbons of said rings being attached to an oxygen to form keto groups and said 4, 5, 6 or 7 membered ring optionally being condensed with an aromatic or non-aromatic 5 or 6 membered ring that optionally includes 1 or heteroatoms selected from N, O and S;
R 3 is independently selected from H, alkyl of 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons, aryl-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons or hetero-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or R 3 is CO—R 7 , SO 2 R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, alkyl of 1 to 20 carbons substituted with and NH 2 group or with an NH—COalkyl group where the alkyl group has one to 6 carbons aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons or heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
the wavy lines represent bonds connected to carbons having R or S configuration;
the dashed lines represent a bond or absence of a bond with the proviso that the ring containing the dashed lines is aromatic;
R 9 and R 10 are one of the combinations selected from the group consisting of (1) R 9 is NOR 11 and R 10 does not exist, (2) R 9 is OR 11 and R 10 is alkyl of 1 to 6 carbons, (3) when the dashed lines between carbons 2 and 3 of the propionic acid moiety represent a bond then R 9 is H or alkyl of 1 to 6 carbons and R 10 does not exist;
R 11 is H, alkyl of 1 to 6 carbons or CO—R 12 where R 12 is alkyl of 1 to 6 carbons;
m, n and q are integers independently selected from 0, 1, 2 or 3 with the proviso that the sum of m, n and q is 2 or 3;
is zero (0) or when X is N then s is zero (0) or 1;
W, X and Y independently represent a CH, CR 5 , CR 6 or a heteroatom selected independently of N, O and S, and
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, halogen substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, phenyl, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 12 groups where R 12 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons or a pharmaceutically acceptable salt of said compound.
29 . The use of claim 28 , wherein the sum of the integers m, n and q is 3.
30 . The use of claim 28 , wherein one of the W, X and Y groups is N.
31 . The use of claim 28 , wherein the R 1 and R 2 groups together with the nitrogen form a 5-membered ring.
32 . The use of claim 28 , wherein R 9 is NOR 11 and R 10 does not exist.
33 . The use of claim 28 , wherein R 9 is methyl and R 10 is OR 11 .
34 . The use of claim 28 , wherein the dashed line between carbons 2 and 3 represents a bond.
35 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
36 . The use of claim 35 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
37 . The use of claim 35 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
38 . The use of claim 35 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
39 . The use of claim 35 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
40 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
41 . The use of claim 40 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
42 . The use of claim 40 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
43 . The use of claim 40 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
44 . The use of claim 40 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
45 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
46 . The use of claim 45 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
47 . The use of claim 45 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
48 . The use of claim 45 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
49 . The use of claim 45 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
50 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
51 . The use of claim 50 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
52 . The use of claim 50 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
53 . The use of claim 50 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
54 . The use of claim 50 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
55 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure
56 . The use of claim 55 , wherein the compound is (2S,3S)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
57 . The use of claim 55 , wherein the compound is (2S,3R)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
58 . The use of claim 55 , wherein the compound is (2R,3S)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
59 . The use of claim 55 , wherein the compound is (2R,3R)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
60 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure
61 . The use of claim 60 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
62 . The use of claim 60 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
63 . The use of claim 60 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
64 . The use of claim 60 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
65 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
66 . The use of claim 65 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
67 . The use of claim 65 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
68 . The use of claim 65 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
69 . The use of claim 65 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
70 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
71 . The use of claim 70 , wherein the compound is (2S,3S)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
72 . The use of claim 70 , wherein the compound is (2S,3R)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
73 . The use of claim 70 , wherein the compound is (2R,3S)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
74 . The use of claim 70 , wherein the compound is (2R,3R)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
75 . The use according to any of the preceding claims, wherein the cognitive disorder is selected from the group consisting of an agnosia, an amnesia, an aphasia, an apraxia, a delirium, a dementia, and a learning disorder.
76 . The use according to claim 75 , wherein the cognitive disorder is selected from the group consisting of AIDS dementia complex, Binswanger's disease, dementia with Lewy Bodies, frontotemporal dementia, mild cognitive impairment, multi-infarct dementia, Pick's disease, semantic dementia, senile dementia, and vascular dementia.
77 . The use according to claim 75 , wherein the learning disorder is selected from the group consisting of Asperger's syndrome, attention deficit disorder,
attention deficit hyperactivity disorder, autism, childhood disintegrative disorder, and Rett syndrome.
78 . The use according to claim 75 , wherein the aphasia is progressive non-fluent aphasia.
79 . The use according to any of the preceding claims, wherein the cognitive disorder is associated with neurodegenerative disease, injury to the brain, psychiatric disorders, or chronic pain.
80 . The use according to claim 79 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, corticobasal degeneration, Creutzfeldt-Jacob disease, frontotemporal lobar degeneration, Huntington disease, multiple sclerosis, normal pressure hydrocephalus, organic chronic brain syndrome, Parkinson's disease, Pick disease, progressive supranuclear palsy, and senile dementia (Alzheimer type).
81 . The use according to claim 79 , wherein the injury to the brain is selected from the group consisting of chronic subdural hematoma, concussion, intracerebral hemorrhage, encephalitis, meningitis, septicemia, drug intoxication, and drug abuse.
82 . The use according to claim 79 , wherein the psychiatric disorders are selected from the group consisting of anxiety disorders, dissociative disorders, mood disorders, schizophrenia, and somatoform and factitious disorders.Join the waitlist — get patent alerts
Track US2014179925A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.